<DOC>
	<DOCNO>NCT01370863</DOCNO>
	<brief_summary>The purpose trial investigate pharmacodynamic effect reflux parameter SPD557 tablet ( 0.5 mg t.i.d. , top PPI treatment ) patient Gastroesophageal Reflux Disease ( GERD ) persistent symptom despite take stable dose proton pump inhibitor . Additionally effect symptom explore safety tolerability evaluate .</brief_summary>
	<brief_title>An Explorative Trial Evaluate Pharmacodynamic Effect SPD557 Reflux Parameters Refractory GERD Patients</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<criteria>Inclusion criterion : 1 . Written ICF sign voluntarily first trial relate activity . 2 . Subjects history GERD symptom ( i.e. , heartburn and/or regurgitation ) last 6 month 3 . Subjects stable dose PPIs , compliant least 6 week prior screen . 4 . â‰¥3 day per week heartburn and/or regurgitation symptom least moderate severity minimum 25 liquid contain reflux event 24h ( pH/MII monitoring ) . Exclusion criterion : 1 . Subjects prior endoscopic antireflux procedure major GI surgery subject major GI disorder . 2 . Presence severe clinically uncontrolled cardiovascular , liver lung disease , neurologic , cancer AIDS . 3 . Alarm symptom suggestive malignancy organic disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>GERD</keyword>
	<keyword>Gastroesophageal reflux disease</keyword>
	<keyword>SPD557</keyword>
	<keyword>Proton pump inhibitor</keyword>
</DOC>